Immune Design (IMDZ) Misses Q4 EPS by 6c

Immune Design (NASDAQ: IMDZ) reported Q4 EPS of ($0.60), $0.06 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.06 million.

For earnings history and earnings-related data on Immune Design (IMDZ) click here.

You May Also Be Interested In

• AEVEX Corp. (AVEX) Reports Q2 EPS of $0.01; offers guidance
• Cisco Systems (CSCO) Tops Q4 EPS by 5c; offers guidance
• Alpha & Omega Semiconductor (AOSL) Tops Q4 EPS by 11c